Keywords: Gilead Sciences, YM BioSciences, M&A, Cancer drug candidate, CYT387

Gilead agrees to buy YM BioSciences for $510 million

Article | 13 December 2012

Print This

US biotechnology firm Gilead Sciences (Nasdaq: GILD) has agreed to acquire Canada's YM BioSciences (TSX: YM) in a deal that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in